WHAT IS CLAIMED IS:

1. A method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a non-replicating adenovirus vector, wherein said vector comprises a polynucleotide which comprises a fas-chimera transgene transcriptionally linked to a murine pre-proendothelin promoter, wherein said therapeutically effective amount is at least $1X10^8$ virus particles.

2. The method of claim 1, wherein said therapeutically effective amount is at least about $1X10^9$ to about $1X10^{16}$ virus particles.

3. The method of claim 1, wherein said therapeutically effective amount is at least about $1X10^{11}$ to about $1X10^{13}$ virus particles.

4. The method of claim 1, wherein said therapeutically effective amount is at least about $3X10^{12}$ virus particles.

5. The method of claim 1, wherein said therapeutically effective amount is at least about $1X10^{13}$ virus particles.

6. The method of claim 1, wherein said fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 2.

7. The method of claim 1, wherein said fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 3.

8. The method of claim 1, wherein said fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 4.

9. The method of claim 1, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 6.

10. The method of claim 1, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 8.

11. The method of claim 1, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 7.

12. The method of claim 1, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 13.

13. The method of claim 1, wherein said murine pre-proendothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 12.

14. The method of claim 1, wherein said murine pre-proendothelin promoter further comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 5.

15. The method of claim 1, wherein said non-replicating adenovirus vector is an adenovirus 5 vector.

16. The method of claim 1, wherein said adenovirus vector comprises a nucleic acid sequence as set forth in SEQ ID NO: 9 or 10.

17. The method of claim 1, wherein said solid tumor is a cancer.

18. The method of claim 1, wherein said solid tumor is a primary tumor.

19. The method of claim 1, wherein said solid tumor is a metastatic tumor.

20. The method of claim 1, wherein said adenovirus vector is administered systemically.

21. The method of claim 20, wherein said vector is administered systemically by a route selected from the group consisting of intra-articular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, infusion, oral administration, rectal administration, nasal administration and inhalation.

22. The method of claim 1, comprising administering said adenovirus vector in at least two separate systemic doses.

23. The method of claim 1, wherein said adenovirus is detected in the blood of said subject at least about 4 days post administration.

24. The method of claim 1, wherein an amount of serum anti-adenovirus antibodies is increased following said administering, and said adenovirus is detected in the blood of said subject at least about 21 days post administration.

25. A method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a non-replicating adenovirus vector which comprises a polynucleotide comprising a fas-chimera transgene transcriptionally linked to a murine pre-proendothelin promoter, said adenovirus vector comprising a nucleic acid sequence as set forth in SEQ ID NO: 9 or 10.

26. The method of claim 25, wherein said therapeutically effective amount is at least about $1X10^{8}$ to about $1X10^{16}$ virus particles.

27. The method of claim 25, wherein said therapeutically effective amount is at least about $1X10^{11}$ to about $1X10^{13}$ virus particles.

28. The method of claim 25, wherein said therapeutically effective amount is at least about $3X10^{12}$ virus particles.

29. The method of claim 25, wherein said therapeutically effective amount is at least about $1X10^{13}$ virus particles.

30. The method of claim 25, wherein said solid tumor is a cancer.

31. The method of claim 25, wherein said solid tumor is a metastatic tumor.

32. The method of claim 25, wherein said solid tumor is a primary tumor.

33. The method of claim 25, wherein said adenovirus vector is administered systemically.

34. The method of claim 33, wherein said vector is administered systemically by a route selected from the group consisting of intra-articular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, infusion, oral administration, rectal administration, nasal administration and inhalation.

35. The method of claim 25, comprising administering said adenovirus vector in a first dose and at least a second additional dose, wherein said first dose is sufficient to induce anti-Ad5 antibodies in said subject, and wherein the time between administration of said first dose and said at least a second dose is sufficient for anti-Ad5 antibody formation in said subject.

36. The method of claim 25, wherein said adenovirus is detected in the blood of said subject at least about 4 days post administration.

37. The method of claim 36, wherein an amount of serum anti-adenovirus antibodies is increased following said administering, and the adenovirus is detected in the blood of said subject at least about 21 days post administration.

38. A method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject, in at least two separate doses, a therapeutically effective amount of a non-replicating adenovirus vector which comprises a polynucleotide comprising a fas-chimera transgene transcriptionally linked to a murine pre-proendothelin promoter wherein said administration does not induce a dose-dependent increase in antibodies against said adenoviral vector in said subject.

39. The method of claim 38, wherein said therapeutically effective amount is at least about $1X10^{8}$ to about $1X10^{16}$ virus particles.

40. The method of claim 38, wherein said therapeutically effective amount is at least about $1X10^{11}$ to about $1X10^{13}$ virus particles.

41. The method of claim 38, wherein said therapeutically effective amount is at least about $3X10^{12}$ virus particles.

42. The method of claim 38, wherein said therapeutically effective amount is at least about $1X10^{13}$ virus particles.

43. The method of claim 38, wherein said fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 2.

44. The method of claim 38, wherein said fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 3.

45. The method of claim 38, wherein said fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 4.

46. The method of claim 38, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 6.

47. The method of claim 38, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 8.

48. The method of claim 38, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 7.

49. The method of claim 38, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 13.

50. The method of claim 38, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 12.

51. The method of claim 38, wherein said murine pre-proendothelin promoter further comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 5.

52. The method of claim 38, wherein said non-replicating adenovirus vector is an adenovirus 5 vector.

53. The method of claim 38, wherein said adenovirus 5 vector comprises a nucleic acid sequence as set forth in SEQ ID NO: 9 or 10.

54. The method of claim 38, wherein said solid tumor is a cancer.

55. The method of claim 38, wherein said solid tumor is a primary tumor.

56. The method of claim 38, wherein said solid tumor is a metastatic tumor.

57. The method of claim 38, wherein said adenovirus vector is administered systemically.

58. The method of claim 38, wherein said vector is administered systemically by a route selected from the group consisting of intra-articular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, infusion, oral administration, rectal administration, nasal administration and inhalation.

59. The method of claim 38, wherein said adenovirus is detected in the blood of said subject at least about 4 days post administration.

60. The method of claim 59, wherein an amount of serum anti-adenovirus antibodies is increased following said administering, and the adenovirus is detected in the blood of said subject at least about 21 days post administration.

61. A method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject a single intravenous dose of $3X10^{12}$ or $1X10^{12}$ virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 9 or 10.

62. The method of claim 61, wherein said solid tumor is a cancerous tumor.

63. The method of claim 61, wherein said solid tumor is a primary tumor.

64. The method of claim 61, wherein said solid tumor is a metastatic tumor.

65. The method of claim 61, wherein administering said dose of adenovirus vector inhibits angiogenesis of said tumor.

66. The method of claim 61, wherein said administering said dose of adenovirus inhibits growth of said tumor.

67. The method of claim 61, wherein said adenovirus is detected in the blood of said subject at least about 4 days post administration.

68. The method of claim 67, wherein said subject has elevated serum anti-adenovirus antibodies compared to pre-treatment anti-adenovirus antibody levels, and said adenovirus is detected in the blood of said subject at least about 21 days post administration.

69. A method of treating a thyroid cancer in a subject in need thereof, the method comprising administering to the subject a single intravenous dose of $3X10^{12}$ or $1X10^{13}$ virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 9 or 10.

70. The method of claim 69, wherein said therapeutically effective amount is at least about $1X10^{13}$ virus particles.

71. A method of treating a neuroendocrine cancer in a subject in need thereof, the method comprising administering to the subject a single intravenous dose of $3X10^{12}$ or $1X10^{13}$ virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 9 or 10.

72. The method of claim 71, wherein said therapeutically effective amount is at least about $1X10^{13}$ virus particles.

73. A kit for treating a solid tumor in a subject in need thereof, comprising a unit dosage of virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 9 or 10 wherein said non-replicating adenovirus vector is formulated for intravenous administration, and instructions for administration of said adenovirus.

74. The kit of claim 73, wherein said unit dosage comprises about $3X10^{12}$ virus particles.

75. The kit of claim 73, wherein said unit dosage comprises at least about $1X10^{13}$ virus particles.

76. A method for administering a therapeutic composition comprising an adenoviral vector to a subject, comprising administering a therapeutically effective amount of the composition to the subject at least twice, wherein the administering does not induce a dose-dependent increase in anti-adenovirus antibodies against said adenoviral vector in the subject.

77. The method of claim 76, wherein said therapeutically effective amount is at least about $1X10^{8}$ to about $1X10^{16}$ virus particles.

78. The method of claim 76, wherein said therapeutically effective amount is at least about $1X10^{11}$ to about $1X10^{13}$ virus particles.

79. The method of claim 76, wherein said therapeutically effective amount is at least about $3X10^{12}$ virus particles.

80. The method of claim 76, wherein said therapeutically effective amount is at least about $1X10^{13}$ virus particles.

81. The method of claim 76, wherein said adenovirus is detected in the blood of said subject at least about 4 days post administration.

82. The method of claim 81, wherein an amount of serum anti-adenovirus antibodies is increased following said administering, and said adenovirus is detected in the blood of said subject at least about 21 days post administration.

83. The method of any one of claims 1 to 72, wherein said subject is further receiving a chemotherapeutic agent as well as treatment with said virus particles of said non-replicating adenovirus vector.

84. The method of claim 83, wherein said chemotherapeutic agent is administered prior to treatment with said virus particles.

85. The method of claim 83, wherein said chemotherapeutic agent is administered concomitantly with treatment with said virus particles.

86. The method of claim 83, wherein said chemotherapeutic agent is administered following treatment with said virus particles.

87. The method of claim 83, wherein said chemotherapeutic agent is sunitinib.

WHAT IS CLAIMED IS:

1. A method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject, in at least two separate doses, a therapeutically effective amount of a non-replicating adenovirus vector which comprises a polynucleotide comprising a fas-chimera transgene transcriptionally linked to a murine pre-proendothelin promoter wherein said administration does not induce a dose-dependent increase in antibodies against said adenoviral vector in said subject.

2. The method of claim 1, wherein said therapeutically effective amount is at least about $1X10^{8}$ to about $1X10^{16}$ virus particles.

3. The method of claim 1, wherein said therapeutically effective amount is at least about $1X10^{11}$ to about $1X10^{13}$ virus particles.

4. The method of claim 1, wherein said therapeutically effective amount is at least about $3X10^{12}$ virus particles.

5. The method of claim 1, wherein said therapeutically effective amount is at least about $1X10^{13}$ virus particles.

6. The method of claim 1, wherein said fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 2.

7. The method of claim 1, wherein said fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 3.

8. The method of claim 1, wherein said fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 4.

9. The method of claim 1, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 6.

10. The method of claim 1, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 8.

11. The method of claim 1, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 7.

12. The method of claim 1, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 13.

13. The method of claim 1, wherein said murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 12.

14. The method of claim 1, wherein said murine pre-proendothelin promoter further comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 5.

15. The method of claim 1, wherein said non-replicating adenovirus vector is an adenovirus 5 vector.

16. The method of claim 1, wherein said adenovirus 5 vector comprises a nucleic acid sequence as set forth in SEQ ID NO: 9 or 10.

17. The method of claim 1, wherein said solid tumor is a cancer.

18. The method of claim 1, wherein said solid tumor is a primary tumor.

19. The method of claim 1, wherein said solid tumor is a metastatic tumor.

20. The method of claim 1, wherein said adenovirus vector is administered systemically.

21. The method of claim 1, wherein said vector is administered systemically by a route selected from the group consisting of intra-articular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, infusion, oral administration, rectal administration, nasal administration and inhalation.

22. The method of claim 1, wherein said adenovirus is detected in the blood of said subject at least about 4 days post administration.

23. The method of claim 22, wherein an amount of serum anti-adenovirus antibodies is increased following said administering, and the adenovirus is detected in the blood of said subject at least about 21 days post administration.